A Nature Research Service

Oncology

The latest from BioPharma Dealmakers on companies, research and deals in the oncology field.

Revolutionizing the way cancer is diagnosed

Sponsor content

Revolutionizing the way cancer is diagnosed

Jun 06, 2017

Merus June 2017

Sponsor content

Merus June 2017

Jun 05, 2017

Driving innovation through early-stage investments

Sponsor content

Driving innovation through early-stage investments

Jun 05, 2017

Changing the fate of cellular immunotherapy

Sponsor content

Changing the fate of cellular immunotherapy

Fate Therapeutics

Jun 02, 2017

Redefining cancer therapy with photoimmunotherapy

Sponsor content

Redefining cancer therapy with photoimmunotherapy

Aspyrian Therapeutics

Jun 02, 2017

Enzyme engineering for rare genetic diseases and cancer

Sponsor content

Enzyme engineering for rare genetic diseases and cancer

Aeglea Biotherapeutics

Jun 02, 2017

Sponsor content

Lantern Pharma: precision medicine pioneers

Mar 02, 2017

Read our March 2017 issue.

Editorial content

Dermatology, Gastrointestinal , Oncology, March 2017

Read our March 2017 issue.

Raveena Bhambra

Mar 01, 2017

TheraMAB starts oncology clinical program with its mAb targeting an immune checkpoint

Sponsor content

TheraMAB starts oncology clinical program with its mAb targeting an immune checkpoint

Mar 01, 2017

Sponsor content

Enhanced immuno-viral therapy for solid tumors

Icell Kealex Therapeutics

Mar 01, 2017

Sponsor content

Enabling solid tumor T cell therapies and checkpoint inhibitors with oncolytic adenoviruses

Tilt Biotherapeutics

Feb 28, 2017

Sponsor content

Reformulating a novel therapeutic for lung cancer

Feb 24, 2017

Unravelling the potential of nucleic-acid-based drugs

Premium Content Editorial content

Drug Development , Infectious Diseases, Oncology, November 2016

Unravelling the potential of nucleic-acid-based drugs

BioPharma Dealmakers

Nov 23, 2016

Sponsor content

Oncology, November 2016

Astex targets CNS with fragment-based approach

Astex Pharmaceuticals

Oct 25, 2016

Charting checkpoint inhibitors

Premium Content Editorial content

Deal Trends, Oncology, September 2016

Charting checkpoint inhibitors

BioPharma Dealmakers

Oct 17, 2016

Sponsor content

Oncology, September 2016

Fusion cancer vaccine targets combination therapy trials

Sep 06, 2016

Sponsor content

Oncology, September 2016

Amunix unveils next-generation immunooncologic cancer therapy platform

Sep 05, 2016

Sponsor content

Oncology, June 2016

Pioneering precision medicine by tailoring the right drugs to the right cancer patients

May 20, 2016

Sponsor content

Oncology, June 2016

Enzyme engineering for rare disease and cancer

Aeglea Biotherapeutics

May 19, 2016

Sponsor content

Oncology, March 2016

Working with a genomics pioneer to develop safer, more effective cancer treatments

OncoTherapy Science

Mar 02, 2016